RayKnowChina Research Map
Shortlist

Not yet recruitingCongenital heart diseasePhase 4

Registered title, quoted from ClinicalTrials.gov

Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery

An open trial on congenital heart disease, registered on ClinicalTrials.gov. Led by Children's Hospital, Zhejiang University School of Medicine; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorChildren's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07499154, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. Not stated to 12 months; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07499154, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Infants aged 0 to 12 months.
  • Congenital heart disease requiring corrective, non-palliative cardiac surgery with cardiopulmonary bypass.
  • American Society of Anesthesiologists (ASA) physical status I to III.
  • Written informed consent provided by parent(s) or legal guardian(s).

Exclusion Criteria:

  • Multiple malformations, chromosomal abnormalities, or immunodeficiency.
  • Known or suspected allergy to lidocaine.
  • Concomitant continuous infusion of another local anesthetic.
  • Conditions associated with increased risk of lidocaine accumulation or toxicity, including severe conduction block or severe bradycardia.
  • ASA physical status IV or higher.
  • Severe malnutrition expected to substantially impair postoperative recovery.
  • Severe hepatic or renal dysfunction.
  • Significant pre-existing pulmonary disease or markedly impaired preoperative pulmonary function.
  • Central nervous system disorders that may increase susceptibility to lidocaine neurotoxicity, including epilepsy or prior central nervous system infection.
  • Use of medications that may interact with lidocaine or constitute an exclusion, including class I or class III antiarrhythmic agents, cimetidine, or antiviral drugs, as determined by the clinical team.
  • Current or recent participation in another interventional clinical trial in its active intervention phase.

Quoted from ClinicalTrials.gov, NCT07499154, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07499154, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07499154